This study retrospectively analysed clinical data from patients with metastatic HR-positive breast cancer treated with CDK4/6 inhibitors, revealing that a high BMI was linked to poorer overall survival outcomes following CDK4/6 inhibitor therapy. Here, CDK4 is linked to breast carcinoma.